Establishing an efficient operational strategy from the start in order to launch a successful trial

Size: px
Start display at page:

Download "Establishing an efficient operational strategy from the start in order to launch a successful trial"

Transcription

1 Establishing an efficient operational strategy from the start in order to launch a successful trial Dr. Gerald Grossheinrich-Pitschke Head Clinical Trial Delivery 5th Clinical Trials Innovation Program (CTIP) June 27-28, Hamburg, Germany

2 Disclaimer The views and opinions expressed in the following presentation are those of the individual presenter and should not be attributed to any organization with which the presenter is employed or affiliated Seite 2

3 From an operational perspective what does succesful mean? Recruitment hits the target What could be the reasons that clinical trials miss the target? The protocol is the basis for a successful clinical trial The Set-up is the second important pillar Typical challenges during Set-up can be linked to: The Do-ability has gaps Feasibility is not well-thought through Planning is too optimistic Do you have the right Outsourcing model? Seite 3

4 Outsourcing models Outsourcing Strategies and Practices to Improve Efficiency and Performance; Aug 11, 2015; By Mary Jo Lamberti, PhD, Frances Grote, Murray A. Abramson, MD, Kenneth A. Getz; Applied Clinical Trials Seite 4

5 Drivers for Outsourcing? What are the drivers for outsourcing? Nice Insight survey during ; Seite 5

6 How to shape collaboration? What can be done to optimize the collaboration between Sponsor and Service Provider (SP)? Sponsors and Service Providers sometimes mention the following as areas which need to be considered: Trust Transparency Communication style Adaption of processes Clear responsibilities Seite 6

7 How to collaborate best? An outsourcing model should enhance the collaboration between Sponsor and Service Provider. This will improve the relationship and increase performance and efficiency. If this works during the Set-up phase then this will work during the conduct of the trial too. Seite 7

8 Simplification To simplify the collaboration with your SP carefully think about the Standard Operating Procedures (SOPs) to be used during the clinical trial. Further avenues need to be examined as well, including: Documents Systems Contracting Handovers Seite 8

9 Communication Service Providers and Sponsors need to be partners during the clinical trial in order to: Discuss on an equal level Increase transparency Exchange of expectations don t forget to document those in - contracts - operational manual - decision logs Seite 9

10 Innovation Less than half of clinical trials conducted today incorporate some type of innovative component. * * Innovations could be: Usage of online pre-screening before site initiation Using data on site-performance from thousands of trials Usage of electronic Informed Consent Form (eicf) *The 2015 Avoca Report - Clinical Development Innovation Seite 10

11 Specialization & Training Clinical Research in general has become much more complex than in the past. Therefore, it becomes consistently more important to retain trained and qualified individuals for as long as possible and create specialized groups like a Trial Set-Up Team Seite 11

12 How to optimize the Set-Up? Leading operational Do-ability for each envisaged country collecting information on: standard of care availability of comparator export/import requirements regulatory requirements patient organizations local treatment guidance Preparation of a well-thought operational feasibility Support selection of potential sites Seite 12

13 How to optimize the Set-Up? Planning and defining the recruitment strategy involvement of professional patient recruitment organization(s) involvement of patient interest/advocacy groups compensatory (back-up) strategies from beginning clarity on wanted and needed countries Raise awareness of all anticipated risks - develop mitigation strategy before things do not go according to plan Creation of project plan with reasonable milestones Plan your budget don t underestimate the costs Seite 13

14 Performance Most Key Performance Indicators (KPIs) defined in the literature assess the performance after First Subject In (FSI). However, most critical is the Set-up phase of a clinical trial. A correction of an suboptimal Set-Up after FSI costs a lot of time and money. A bad performance during the Set-Up phase is hard to detect. KPIs could be: % of sites actively contributing to online pre-screening before site initiation % of submissions according to planned target Number of major protocol revisions EUCROF WEBINAR - 21Apr2016 Performance metrics in the collaboration between Sponsor and CRO, Philippe Van der Hofstadt, CEO of B&C Group Antoinette van Dijk, Chair Working Group Education & Training EUCROF Seite 14

15 Summary GRÜNENTHAL Name der Präsentation Datum Seite 15

16 Summary How to establish an efficient operational strategy from the start in order to launch a successful trial? The following parameters should be considered: Do-ability (protocol) Feasibility (country & sites) Selection of potential sites Define recruitment strategy incl. back-up strategy Creation of project plan Budget plan Seite 16

17 Thanks for listening Dr. Gerald Grossheinrich gerald.grossheinrich-pitschke[at]grunenthal[dot]com GRÜNENTHAL Name der Präsentation Datum Seite 17

White Paper INTRODUCING A COMPLEXITY SCORING SYSTEM IN CONTRACT NEGOTIATION

White Paper INTRODUCING A COMPLEXITY SCORING SYSTEM IN CONTRACT NEGOTIATION White Paper INTRODUCING A COMPLEXITY SCORING SYSTEM IN CONTRACT NEGOTIATION Table of Contents 1. Introduction... 3 2. The Key Drivers For Study Startup Performance... 3 3. Contracts Negotiation Parallel

More information

Meeting sponsor s criteria : strategy to collaborate, engage and deliver

Meeting sponsor s criteria : strategy to collaborate, engage and deliver Meeting sponsor s criteria : strategy to collaborate, engage and deliver Frédérique Couttet Clinical Trial Manager 4th Annual Outsourcing in Clinical Trials Europe Brussels, Switzerland, May 21 22, 2014

More information

CRO Oversight - Laissez-faire vs. Micromanagement - oder: Wie viel ist zu viel?

CRO Oversight - Laissez-faire vs. Micromanagement - oder: Wie viel ist zu viel? CRO Oversight - Laissez-faire vs. Micromanagement - oder: Wie viel ist zu viel? X. Interdisziplinaeres Expertengespraech, PPH plus Frankfurt, Mai 8 th, 2015 Jens Opitz Head Corporate Clinical Operations

More information

The Safety Case as a basis for more effective outsourcing of writing of aggregate safety reports

The Safety Case as a basis for more effective outsourcing of writing of aggregate safety reports The Safety Case as a basis for more effective outsourcing of writing of aggregate safety reports Dr Brian Edwards Scientific Adviser, Pharmacovigilance & Drug Safety, NDA Regulatory Science Ltd DIA 3rd

More information

FRAMEWORK OF CHARACTERISTICS OF A QUALIFIED SITE TEAM: How Does Yours Measure Up?

FRAMEWORK OF CHARACTERISTICS OF A QUALIFIED SITE TEAM: How Does Yours Measure Up? FRAMEWORK OF CHARACTERISTICS OF A QUALIFIED SITE TEAM: How Does Yours Measure Up? The following framework of characteristics focuses on attributes that are within the control of investigators and their

More information

What Could Go Wrong? ICH E6 R2, Investigative Sites and Risk Assessment Module 2 of a 4 Part Series

What Could Go Wrong? ICH E6 R2, Investigative Sites and Risk Assessment Module 2 of a 4 Part Series What Could Go Wrong? ICH E6 R2, Investigative Sites and Risk Assessment Module 2 of a 4 Part Series Jill Collins Executive Director, Global Operations Management, Syneos Health Mike Walega Executive Director,

More information

EUCROF Presentation. EMA Roundtable meeting with stakeholders on the 10-year anniversary of the SME Office. 27 November 2015 London

EUCROF Presentation. EMA Roundtable meeting with stakeholders on the 10-year anniversary of the SME Office. 27 November 2015 London EUCROF Presentation EMA Roundtable meeting with stakeholders on the 10-year anniversary of the SME Office 27 November 2015 London Dr. Stefano Marini, MD EUCROF President European Contract Research Organization

More information

Welcome. Thank you for joining us. Irina Moissiu, Director Client Relations Laurie Furiness, EVP Operations & Consulting Services

Welcome. Thank you for joining us. Irina Moissiu, Director Client Relations Laurie Furiness, EVP Operations & Consulting Services Welcome Thank you for joining us Irina Moissiu, Director Client Relations Laurie Furiness, EVP Operations & Consulting Services 360 o SERVICE PERFORMANCE MEASUREMENT Sponsor View TM 5 Assessments Available

More information

CRO/SPONSOR COOPERATION: COLLABORATING FOR A SUCCESSFUL OUTCOME

CRO/SPONSOR COOPERATION: COLLABORATING FOR A SUCCESSFUL OUTCOME CRO/SPONSOR COOPERATION: COLLABORATING FOR A SUCCESSFUL OUTCOME Vibeke Breinholt Director, Clinical Operations, Ferring Pharmaceuticals A/S 18 September 2014 Presentation Overview 1. How to choose the

More information

KPI ENCYCLOPEDIA. A Comprehensive Collection of KPI Definitions for PHARMACEUTICALS

KPI ENCYCLOPEDIA. A Comprehensive Collection of KPI Definitions for PHARMACEUTICALS KPI ENCYCLOPEDIA A Comprehensive Collection of KPI Definitions for PHARMACEUTICALS www.opsdog.com info@opsdog.com 844.650.2888 Table of Contents Pharmaceuticals KPI Encyclopedia Pharmaceuticals Metric

More information

How to rescue a clinical trial

How to rescue a clinical trial How to rescue a clinical trial Clinical trial conduct is demanding and rigorous, especially in orphan indications where patient populations are small. Even well-qualified, specifically selected Contract

More information

Risk Management in Clinical Trials in Today s ICH-GCP(R2) Framework

Risk Management in Clinical Trials in Today s ICH-GCP(R2) Framework Clinical Research in Resource Limited Settings: Mission Impossible or Role Model for Future Drug Development? Risk Management in Clinical Trials in Today s ICH-GCP(R2) Framework Ingrid Klingmann, MD, PhD,

More information

Creating the ideal Approach to gain Balance between effective Oversight and Micromanaging

Creating the ideal Approach to gain Balance between effective Oversight and Micromanaging Creating the ideal Approach to gain Balance between effective Oversight and Micromanaging Karine Pigache-Renard and on behalf of Ulrike M. Grimm 4 th Annual Outsourcing in Clinical Trials Europe Conference,

More information

PAREXEL STRATEGIC PARTNERSHIPS. Optimizing relationships for shorter time to market

PAREXEL STRATEGIC PARTNERSHIPS. Optimizing relationships for shorter time to market PAREXEL STRATEGIC PARTNERSHIPS Optimizing relationships for shorter time to market YOUR JOURNEY. OUR MISSION. Delivering a more collaborative and operationally efficient relationship so you can reach your

More information

Effective Project Leadership and Management: Disclaimer

Effective Project Leadership and Management: Disclaimer Effective Project Leadership and Management: A CRO Perspective Nita Ichhpurani, B.S., PMP Director, Drug Development Disclaimer The views and opinions expressed in the following PowerPoint slides are those

More information

Leading Provider of Technology-Enabled Solutions for Clinical Research

Leading Provider of Technology-Enabled Solutions for Clinical Research Leading Provider of Technology-Enabled Solutions for Clinical Research SUCCESSFUL CLINICAL TRIALS REQUIRE THE ABILITY TO SEE KEY DETAILS AND UNCOVER HIDDEN INSIGHTS. utilizes science and technology to

More information

Tackling the Tribulations of Clinical Trials with Research Technology

Tackling the Tribulations of Clinical Trials with Research Technology Tackling the Tribulations of Clinical Trials with Research Technology Kyle Byron Clinical Conductor CTMS Krissy Bouchard Raleigh Neurology October 15, 2016 Faculty Disclosure In compliance with ACCME Guidelines,

More information

Innovative strategies to improve R&D ROI

Innovative strategies to improve R&D ROI Innovative strategies to improve R&D ROI Ed Stelmakh, CPA, CMA Vice President and CFO Otsuka America Pharmaceutical, Inc. DISCLAIMER: The following presentation represents the opinions of the speaker and

More information

Clinical Trial Performance Metrics

Clinical Trial Performance Metrics Clinical Trial Performance Metrics Clinical trial performance metrics? Data points that provide insight into operational and quality of performance. Objectives of Clinical Trial Performance Metrics The

More information

IXRS DATA TO INFORMED DECISION MAKING. Linda Chan-Kim October 2015

IXRS DATA TO INFORMED DECISION MAKING. Linda Chan-Kim October 2015 IXRS DATA TO INFORMED DECISION MAKING Linda Chan-Kim October 2015 Table of Contents Genentech Overview EMMA Data Issues What did we do? 2 2 Roche Group An innovation network 3 South San Francisco is home

More information

Human Research Protection Program Policy

Human Research Protection Program Policy Page 1 of 5 REVIEW OF INVESTIGATIONAL NEW DRUG (IND)/INVESTIGATIONAL DEVICE EXEMPTION (IDE) RESEARCH IN HUMAN SUBJECTS RESEARCH POLICY It is the policy of the University of Cincinnati that studies involving

More information

Recommendations for Strengthening the Investigator Site Community

Recommendations for Strengthening the Investigator Site Community Recommendations for Strengthening the Investigator Site Community October 2017 CTTI MISSION: To develop and drive adoption of practices that will increase the quality and efficiency of clinical trials

More information

Investigational Medicinal Product (IMP) Management Standard Operating Procedure

Investigational Medicinal Product (IMP) Management Standard Operating Procedure Reference Number: UHB 040 Version Number: 3 Date of Next Review: 26 Apr 2019 Previous Trust/LHB Reference Number: T 363 Standard Operating Procedure Introduction and Aim This procedure is written to support

More information

October 25, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852

October 25, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers

More information

Risk-Based Monitoring - Prospective from CRO

Risk-Based Monitoring - Prospective from CRO Risk-Based Monitoring - Prospective from CRO New Trends in Clinical Trials Taipei 2016 Tong Guo, PhD Head of Biostatistics, Africa & Asia QuintilesIMS Copyright 2015 Quintiles Disclaimer The views and

More information

Data-Driven Strategies for Improved Site Activation and Patient Enrollment Forecasting

Data-Driven Strategies for Improved Site Activation and Patient Enrollment Forecasting Data-Driven Strategies for Improved Site Activation and Patient Enrollment Forecasting Introduction PRESENTERS Mark Shapiro, MA, MBA Vice President, Clinical Development Clinipace Worldwide Cindy Venendaal,

More information

Mini Summit IV: Advanced Issues in Transparency and Disclosure - Research and Clinical Trials Update

Mini Summit IV: Advanced Issues in Transparency and Disclosure - Research and Clinical Trials Update Mini Summit IV: Advanced Issues in Transparency and Disclosure - Research and Clinical Trials Update Dr. Jessica Santos Global Compliance and Quality Director 17 August 2015 Meaning of Pharma/Life Science

More information

Veeva 2017 Unified Clinical Operations Survey

Veeva 2017 Unified Clinical Operations Survey PRELIMINARY FINDINGS Veeva 2017 Unified Clinical Operations Survey The Veeva 2017 Unified Clinical Operations Survey examines the life sciences industry s progress toward a unified clinical environment

More information

PERFORMANCE IN INITIATING CLINICAL RESEARCH (PI) CLINICAL TRIAL FEEDBACK PROCESS HRA APPROVED TRIALS

PERFORMANCE IN INITIATING CLINICAL RESEARCH (PI) CLINICAL TRIAL FEEDBACK PROCESS HRA APPROVED TRIALS PERFORMANCE IN INITIATING CLINICAL RESEARCH (PI) CLINICAL TRIAL FEEDBACK PROCESS HRA APPROVED TRIALS Version Control New document 1 Acronyms CTP DSC DSS FPR HRA MHRA REC SOP Clinical Trial Performance

More information

Vendor-Sponsor Successful Communication. Nathalie Dutil Nov 2012

Vendor-Sponsor Successful Communication. Nathalie Dutil Nov 2012 Vendor-Sponsor Successful Communication Nathalie Dutil Nov 2012 It s all about setting expectations. Lack of communication Miscommunication Presentation overview Strategic Sourcing Oversight Model Trust

More information

ENHANCING CLINICAL DATA QUALITY WITH SPECIALIZED FUNCTIONAL SERVICE PROVIDER MODEL

ENHANCING CLINICAL DATA QUALITY WITH SPECIALIZED FUNCTIONAL SERVICE PROVIDER MODEL Shaping the Future of Drug Development ENHANCING CLINICAL DATA QUALITY WITH SPECIALIZED FUNCTIONAL SERVICE PROVIDER MODEL Jim Baker Senior Vice President Clinical Research Services Cytel JIM BAKER Senior

More information

Singapore Clinical Research Professional (CRP) /Clinical Research Coordinator Society (CRCS) Forum

Singapore Clinical Research Professional (CRP) /Clinical Research Coordinator Society (CRCS) Forum Singapore Clinical Research Professional (CRP) /Clinical Research Coordinator Society (CRCS) Forum 25 August 2017 TOPIC: Issue Management / Quality Risk Management Implications with ICH GCP E6 (R2) and

More information

Veeva 2018 Unified Clinical Operations Survey

Veeva 2018 Unified Clinical Operations Survey PRELIMINARY FINDINGS Veeva 2018 Unified Clinical Operations Survey The Veeva 2018 Unified Clinical Operations Survey examines the life sciences industry s progress toward a unified clinical environment

More information

BIOCLINICA SITE & PATIENT PAYMENTS

BIOCLINICA SITE & PATIENT PAYMENTS BIOCLINICA SITE & PATIENT PAYMENTS Improve cash management and financial risk mitigation as well as site payment transparency, control and accuracy, while reducing payment-related workload and costs, with

More information

TransCelerate Overview. Tozheg Roshankar

TransCelerate Overview. Tozheg Roshankar TransCelerate Overview Tozheg Roshankar 11, Aug, 2016 TransCelerate is a not for profit entity created to drive collaboration Our vision To improve the health of people around the world by accelerating

More information

Summary of Day 1. Christopher Granger

Summary of Day 1. Christopher Granger Summary of Day 1 Christopher Granger 508 million tweets Across the globe 2008 to 2010 Science Sept 30 2011 Selected Points Large simple trials are not so simple, and can also be called large streamlined

More information

EU Clinical Trial Regulation A view from the Industry

EU Clinical Trial Regulation A view from the Industry Conference EU Clinical Trial Regulation EU Clinical Trial Regulation A view from the Industry Judith Creba, Executive Director, EU Regulatory Strategy, Novartis Pharma AG University of Basel, Law Faculty

More information

BEST PRACTICES GUIDE COMPLYING WITH THE ICH E6(R2) ADDENDUM

BEST PRACTICES GUIDE COMPLYING WITH THE ICH E6(R2) ADDENDUM BEST PRACTICES GUIDE COMPLYING WITH THE ICH E6(R2) ADDENDUM Six steps to ensuring risk-based quality management in clinical trials EVOLVING REGULATIONS ON RISK-BASED MONITORING In 2016, the International

More information

Realising Leadership (RLP) Achieving manufacturing excellence through leadership

Realising Leadership (RLP) Achieving manufacturing excellence through leadership Realising Leadership Potential (RLP) Achieving manufacturing excellence through leadership Realising Leadership Potential How do we evolve leaders as well as up-skilling managers? The best manufacturing

More information

Multi-Stakeholder Collaborations Can Minimize Barriers & Drive Rare Disease Clinical Programs to Better Patient Outcomes

Multi-Stakeholder Collaborations Can Minimize Barriers & Drive Rare Disease Clinical Programs to Better Patient Outcomes WHITE PAPER Multi-Stakeholder Collaborations Can Minimize Barriers & Drive Rare Disease Clinical Programs to Better Patient Outcomes Author: SCOTT SCHLIEBNER Vice President, Rare Disease - Scientific Affairs

More information

Complex Care Program Development: A New Framework for Design and Evaluation

Complex Care Program Development: A New Framework for Design and Evaluation BRIEF MARCH 2017 Complex Care Program Development: A New Framework for Design and Evaluation By David Labby, MD, PhD * IN BRIEF While medical-technological interventions undergo robust research and design

More information

Project Delivery Excellence

Project Delivery Excellence Project Delivery Excellence Raising the bar in project success 1 ICONplc.com Contents Raising the bar in project success 03 Tailored training and development 04 Project planning and management for predictable

More information

Sponsor/CRO Partnership Optimization

Sponsor/CRO Partnership Optimization Insight Brief Sponsor/CRO Partnership Optimization Developing a CRO Governance Model Geoff Garabedian, Vice President and Managing Director, Consulting at Quintiles Josh Samon, Principal Life Sciences

More information

Exploring the Importance of Instilling a Sense of Ownership in the Vendor and Making Them Feel Involved and Motivated Through the Trial Cycle

Exploring the Importance of Instilling a Sense of Ownership in the Vendor and Making Them Feel Involved and Motivated Through the Trial Cycle Exploring the Importance of Instilling a Sense of Ownership in the Vendor and Making Them Feel Involved and Motivated Through the Trial Cycle Natasha Sabljic November 14, 2012 Outsourcing in Clinical Trials

More information

Corporate Presentation. October 2017

Corporate Presentation. October 2017 Corporate Presentation October 2017 Company Overview OPIS is an international CRO providing: - A wide range of clinical and e-clinical services for Pharmaceutical and Biotechnology Industries, Medical

More information

ELEMENTS OF A DATA MONITORING PLAN

ELEMENTS OF A DATA MONITORING PLAN ELEMENTS OF A DATA MONITORING PLAN Definitions Data Monitoring: The regular evaluation of data and documentation collected during a study to ensure both adherence to the approved investigative plan and

More information

Clinical Trial Outsourcing: A Case Study For Small Biotechnology Companies Operating Globally

Clinical Trial Outsourcing: A Case Study For Small Biotechnology Companies Operating Globally Clinical Trial Outsourcing: A Case Study For Small Biotechnology Companies Operating Globally Cerus Corporation Concord, CA Laurence Corash, MD Chief Medical Officer Meisa Propst, Associate Director Clinical

More information

Incorporating Risk- Based Monitoring Strategies: Challenges in Implementation Sherri Hubby, Director, U.S. Quality Assurance

Incorporating Risk- Based Monitoring Strategies: Challenges in Implementation Sherri Hubby, Director, U.S. Quality Assurance Incorporating Risk- Based Monitoring Strategies: Challenges in Implementation Sherri Hubby, Director, U.S. Quality Assurance 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria. Disclaimer The

More information

STUDY DOCUMENTS. DOCUMENT NO.: CR007 v4.0. Marise Buçukoğlu ISSUE DATE: 07 MAR 2017 EFFECTIVE DATE: 21 MAR INTRODUCTION

STUDY DOCUMENTS. DOCUMENT NO.: CR007 v4.0. Marise Buçukoğlu ISSUE DATE: 07 MAR 2017 EFFECTIVE DATE: 21 MAR INTRODUCTION STUDY DOCUMENTS DOCUMENT NO.: CR007 v4.0 AUTHOR: Marise Buçukoğlu ISSUE DATE: 07 MAR 2017 1 INTRODUCTION 1.1 The Academic & Clinical Central Office for Research & Development (ACCORD) is a joint office

More information

Selecting A Right Patient Recruitment Company: The Key To Success

Selecting A Right Patient Recruitment Company: The Key To Success Selecting A Right Patient Recruitment Company: The Key To Success A R T I C L E Toll Free Number: 1-888-987-2691 www.makrocare.com/mcsmo 1 With current global economic uncertainty, intense global competition,

More information

The Science of Small Clinical Trials

The Science of Small Clinical Trials The Science of Small Clinical Trials Introduction to Small Clinical Trials an Industry Perspective Simon Day, PhD Confucius (allegedly) When it is obvious that the goals cannot be reached, don t adjust

More information

Investigator Satisfaction Survey Marketing department

Investigator Satisfaction Survey Marketing department Investigator Satisfaction Survey 2005 Marketing department 1 Who answered the questionnaire? How do investigators usually contact Clirophtha? Our clinical research activity E-CRFs What do investigators

More information

Constructing an etmf 12/2/2011. consider your current etmf structure!! The do s and don ts of EDM. Disclaimer

Constructing an etmf 12/2/2011. consider your current etmf structure!! The do s and don ts of EDM. Disclaimer Constructing an etmf The do s and don ts of EDM Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug

More information

Talking to Active Investigators: Interview Findings

Talking to Active Investigators: Interview Findings April 5, 2017 Talking to Active Investigators: Interview Findings Terri Hinkley RN, BScN, MBA, CCRC Association for Clinical Research Professionals (ACRP) Active Investigator Interviews Active Investigator:

More information

European Stroke Journal: Declaration Guidelines for Authors

European Stroke Journal: Declaration Guidelines for Authors Table of Contents 1. Human Research and In Vitro Studies... 2 Required Declarations... 2 Example of a completed declarations section... 2 Example of text that should be used if any declaration is not relevant

More information

Compliance Program Guidance Manuals (CPGMs) -1-

Compliance Program Guidance Manuals (CPGMs) -1- Inspector s Preparation for a CI Inspection: FDA Compliance Program & the Records Inventory Jean Toth-Allen, Ph.D. APEC GCP Inspection Workshop May 28, 2008 Compliance Program Guidance Manuals (CPGMs)

More information

The Importance of Feasibility Studies for Oncology Clinical Trials

The Importance of Feasibility Studies for Oncology Clinical Trials The Importance of Feasibility Studies for Oncology Clinical Trials www.ppdi.com Executive Summary The segmenting of the oncology patient population has increased the challenges in designing clinical trials.

More information

Document Title: Annual Progress Reports (APRs) Document Number: 056

Document Title: Annual Progress Reports (APRs) Document Number: 056 Document Title: Annual Progress Reports (APRs) Document Number: 056 Version: 1 Ratified by: Committee Date ratified: 30/11/2017 Name of originator/author: Directorate: Department: Name of responsible individual:

More information

THE NEW PARADIGMS IN ONCOLOGY CLINICAL TRIALS. Quality Risk Assessment (RBM) & electronic Informed Consent (eic)

THE NEW PARADIGMS IN ONCOLOGY CLINICAL TRIALS. Quality Risk Assessment (RBM) & electronic Informed Consent (eic) THE NEW PARADIGMS IN ONCOLOGY CLINICAL TRIALS Quality Risk Assessment (RBM) & electronic Informed Consent (eic) DEFINITION OF RISK The combination of the probability of occurrence of harm and the severity

More information

Outsourcing in Clinical Trials Europe 2014

Outsourcing in Clinical Trials Europe 2014 TIME TO BUST E-RECRUITMENT MYTHS! Outsourcing in Clinical Trials Europe 2014 21-22 May 2014, Brussels, Belgium you not only saved us a couple of months time, but definitively disproved two myths that have

More information

JPMSA JOURNAL OF THE PHARMACEUTICAL MANAGEMENT SCIENCE ASSOCIATION SPRING 2014

JPMSA JOURNAL OF THE PHARMACEUTICAL MANAGEMENT SCIENCE ASSOCIATION SPRING 2014 JPMSA JOURNAL OF THE PHARMACEUTICAL MANAGEMENT SCIENCE ASSOCIATION SPRING 2014 1 ARTICLE 2 Unlocking the Value of Closed Loop Marketing Analytics to Drive Customer Centricity Pratap Khedkar, Managing Principal,

More information

22 nd February Utilizing big data to enhance patient recruitment

22 nd February Utilizing big data to enhance patient recruitment 22 nd February 2017 Utilizing big data to enhance patient recruitment Overview Barriers to recruitment success Current solutions to overcome recruitment barriers Outsourcing (3 rd Party Vendors, CROs)

More information

the council initiative on public engagement

the council initiative on public engagement public engagement at the city of edmonton share your voice shape our city the council initiative on public engagement new public engagement practice and implementation roadmap final report CITY OF EDMONTON

More information

NPSO Ltd. Participant Community Event 17 th January Aldersgate, London. For internal use only

NPSO Ltd. Participant Community Event 17 th January Aldersgate, London. For internal use only Participant Community Event 17 th January 2018 200 Aldersgate, London Agenda 1. NPSO Purpose and Approach 2. NPSO Transition - Programme Status 3. Stakeholder Opportunities & Communications 4. Independent

More information

5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs)

5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs) 5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs) GCP Requirements and Compliance Dr. Katalina Mettke BfArM, Germany Agenda Specialities of Early Development Trials Examples

More information

Veeva 2015 Paperless TMF Survey: Annual Report

Veeva 2015 Paperless TMF Survey: Annual Report Veeva 2015 Paperless TMF Survey: Annual Report REMOVING PAPER FROM THE PROCESS The Veeva 2015 Paperless TMF Survey explores the life sciences industry s progress toward paperless clinical trials by gathering

More information

Sponsors, CROs and all

Sponsors, CROs and all Sponsors, CROs and all the Rest Disclaimer The views and opinions expressed in the following PowerPoint presentation represent the opinions of the author / speaker and should not be construed as the position

More information

Almac ONE: One Unified Clinical Trial Supply Solution

Almac ONE: One Unified Clinical Trial Supply Solution Almac ONE: One Unified Clinical Trial Supply Solution There is ONE solution to solving the challenges of managing multiple supply chain vendors... Almac ONE - Your ONE Unified Solution Solution has redefined

More information

The future and value of innovation in the NHS

The future and value of innovation in the NHS The future and value of innovation in the NHS Royal Academy of Engineering Conference 15 November 2011 Mirella Marlow Programme Director Agenda A few words about NICE A few words about innovation What

More information

Challenges and Opportunities in Pharma: Perspective for an Emerging Middle East April 24th, 2015

Challenges and Opportunities in Pharma: Perspective for an Emerging Middle East April 24th, 2015 Challenges and Opportunities in Pharma: Perspective for an Emerging Middle East 2020 April 24th, 2015 Content Pharma Market Landscape Global Pharma Market Market Categories Middle East Markets Major Challenges

More information

medicines, improving the health of people around the world.

medicines, improving the health of people around the world. TransCelerate BioPharma Inc. is a non-profit organization with a mission to collaborate across the biopharmaceutical research and development community to identify, design and facilitate the implementation

More information

WE CARE MEDTECH.

WE CARE MEDTECH. MEDTECH WE CARE Clinical Research & Development Consulting & Strategy Clinical trials Post-Marketing Observational Studies Market Access www.vivactis.com May 2016 WHAT WE DO Clinical Research & Development

More information

Clinical Trials Series Part II

Clinical Trials Series Part II Clinical Trials Series Part II Agenda Recap December Presentation J. Schmelz Example: New CT from HSC Investigator Non Cancer Clinical Trial J. Bates, P. Miranda Example: New CT from External Entity Non

More information

INTRODUCING CLINIC AUTOMATION IN A PHASE I UNIT WITH END-TO-END E-SOURCE DATA PROCESSING

INTRODUCING CLINIC AUTOMATION IN A PHASE I UNIT WITH END-TO-END E-SOURCE DATA PROCESSING INTRODUCING CLINIC AUTOMATION IN A PHASE I UNIT WITH END-TO-END E-SOURCE DATA PROCESSING Wim Verreth 4 th Annual Outsourcing in Clinical Trials 21-22 May 2014 OUTLINE What is Clinical Automation? Why we

More information

DEVELOPING A PERSUASIVE BUSINESS CASE FOR CRM. Glenda Parker

DEVELOPING A PERSUASIVE BUSINESS CASE FOR CRM. Glenda Parker DEVELOPING A PERSUASIVE BUSINESS CASE FOR CRM Glenda Parker CONTENTS INTRODUCTION 2 1. HAVE AN EXECUTIVE SUMMARY (BUT WRITE IT LAST) 3 2. CLEARLY OUTLINE THE PROJECT PURPOSE 3 3. IDENTIFY ALL KEY STAKEHOLDERS

More information

Vendor Selection: Identifying Effective Procedures & Strategies

Vendor Selection: Identifying Effective Procedures & Strategies Outsourcing Clinical Trials Canada 15 th November 2012 Vendor Selection: Identifying Effective Procedures & Strategies John S Andrews PhD President and CSO, NeurAxon Inc President, Ketogen Inc CSO, Talon

More information

Ethics Committees/IRBs Today: Challenges for Efficiency and Quality

Ethics Committees/IRBs Today: Challenges for Efficiency and Quality Marjorie A. Speers, Ph.D. President and CEO Ethics Committees/IRBs Today: Challenges for Efficiency and Quality Copyright 2013 AAHRPP All rights reserved Goal Clinical Research Globally Access to patients

More information

Food and Drug Administration Guidance: Supervisory Responsibilities of Investigators

Food and Drug Administration Guidance: Supervisory Responsibilities of Investigators Journal of Diabetes Science and Technology Volume 5, Issue 2, March 2011 Diabetes Technology Society REVIEW ARTICLE Food and Drug Administration Guidance: Supervisory Responsibilities of Investigators

More information

FDA Perspective on International Clinical Trials

FDA Perspective on International Clinical Trials FDA Perspective on International Clinical Trials Kassa Ayalew, M.D., M.P.H. Division of Clinical Compliance Evaluation (DCCE) Office of Scientific Investigations (OSI) Center for Drug Evaluation and Research

More information

CRO Outlook 2015: A Paperless Path to a Competitive Advantage

CRO Outlook 2015: A Paperless Path to a Competitive Advantage CRO Outlook 2015: A Paperless Path to a Competitive Advantage Dec 22, 2014 By Jennifer Goldsmith Applied Clinical Trials All signs indicate that 2015 should be another good year for contract research organizations

More information

Highlights of the proposed Clinical Trials Regulation in Europe

Highlights of the proposed Clinical Trials Regulation in Europe Highlights of the proposed Clinical Trials Regulation in Europe Dr Daryl Rees 22 January 2013 Proposed Clinical Trials Regulation On 17July 2012, the Commission adopted the proposal for a "Clinical Trials

More information

Clinical trial applications in the EU and US

Clinical trial applications in the EU and US Clinical trial applications in the EU and US Alain Patat, M.D. Translational Development Wyeth Research Paris, France AGAH-Club Phase 1 1 st Symposium Strasbourg 17-18 March 2005 Overview of the presentation

More information

Timeliness of TMF Document Submission: from Finalized to Filed

Timeliness of TMF Document Submission: from Finalized to Filed Timeliness of TMF Document Submission: from Finalized to Filed Vittoria Sparacio, MSc CBI s etmf Forum Hyatt at de Bellevue Philadelphia 18 November 2014 Finally my turn to say... I know I am standing

More information

Technology to Transform Your Clinical Trials

Technology to Transform Your Clinical Trials Technology to Transform Your Clinical Trials DrugDev Spark is the only unified clinical solutions suite with proven success for hundreds of sponsors and CROs Spark Spark TM DrugDev Spark is the answer

More information

Confirming Research Study Capacity and Capability

Confirming Research Study Capacity and Capability Title: Outcome Statement: Written By: Confirming Research Study Capacity and Capability Researchers will be informed about the procedures and requirements for obtaining permission to conduct a research

More information

Volunteer Coordinator

Volunteer Coordinator Volunteer Coordinator Ronald McDonald House Charities believes that it s people are an essential part of the Charity and value them and their contribution. This Success Profile adds to the overall value

More information

Challenges of Analytical Method Transfer in the Pharmaceutical Industry

Challenges of Analytical Method Transfer in the Pharmaceutical Industry Challenges of Analytical Method Transfer in the Pharmaceutical Industry White Paper Author: Steve Alley, Technical Specialist 1 Contents Introduction 2 Method Transfer Team 3 Identify Methods 4 Gap Analysis

More information

Transparency as a Good Business Practice

Transparency as a Good Business Practice Transparency as a Good Business Practice Exploring How Transparency Can Drive Best Practices in Business Strategy August 2017 Polaris Management Partners Agenda Compliance Trends 2017-2018 Deriving Strategic

More information

Journal of Clinical Urology (JCU): Declaration Guidelines for Authors

Journal of Clinical Urology (JCU): Declaration Guidelines for Authors Table of Contents 1. Case Report or Case Series... 2 Required Declarations... 2 Example of a completed declarations section:... 2 Example of text that should be used if any declaration is not relevant

More information

Streamlining IRB Procedures for Expanded Access

Streamlining IRB Procedures for Expanded Access Streamlining IRB Procedures for Expanded Access Marjorie A. Speers, Ph.D. Executive Director, WCG Foundation Richard Klein Director, FDA Patient Liaison Program Office of Health and Constituent Affairs

More information

Panel Discussion MINI SUMMIT XIII: global fair market value update

Panel Discussion MINI SUMMIT XIII: global fair market value update Panel Discussion MINI SUMMIT XIII: global fair market value update Introduction Panel Swee Kheng Khor, MD, Associate Director, Office of Ethics and Compliance, Middle Eastand Pakistan, AbbVie BioPharmaceutical

More information

Anatomy of an FDA Audit Trigger Prevention and Process

Anatomy of an FDA Audit Trigger Prevention and Process Robert S. Walsh, MD, MBA, FAHA, FCCP Walsh Medical Consulting 15 th Annual Product Complaints Congress Crystal City, VA 14 June 2017 How many here are from Pharma? Medical Device Industry? Biotechnology?

More information

Aspects of IBCs in Multicent Multicen er t Clinical Trials Daniel Kavan Kava agh, PhD

Aspects of IBCs in Multicent Multicen er t Clinical Trials Daniel Kavan Kava agh, PhD Aspects of IBCs in Multicenter Clinical Trials Daniel Kavanagh, PhD Disclosure DGK is employed by WIRB Copernicus Group, a provider of externally administered IBC Services. About Me Senior Director, Biosafety

More information

PhlexEview: Transforming Costly Paper Processes into Value Driven Compliance

PhlexEview: Transforming Costly Paper Processes into Value Driven Compliance PHLEXGLOBAL WHITE PAPER PhlexEview: Transforming Costly Paper Processes into Value Driven Compliance Presented By: Karen Redding Global Business Development Director Phlexglobal, Ltd. kredding@phlexglobal.com

More information

Key Opinion Leader Development. Tony Moses President, A-Z Eye Consultants National Manager, eyecheck LLC

Key Opinion Leader Development. Tony Moses President, A-Z Eye Consultants National Manager, eyecheck LLC Tony Moses President, A-Z Eye Consultants National Manager, eyecheck LLC What defines a KOL? What are the most important KOL activities? Why build a KOL Program? How to build a KOL Program? When to begin

More information

Learning about Clinical Trials

Learning about Clinical Trials Learning about Clinical Trials A Guide for Individuals and Their Loved Ones INTRODUCTION Clinical trials help researchers answer important medical questions, providing information that may help with the

More information

QUALITY quality standard that the data are credible and the rights, safety, integrity and confidentiality of the subjects are protected HOW???

QUALITY quality standard that the data are credible and the rights, safety, integrity and confidentiality of the subjects are protected HOW??? L.Massad GCP an International Ethical and Scientific quality standard by which clinical trials are designed, implemented and reported so that there is public assurance that the data are credible and the

More information

Challenges of Multicenter Studies in Europe, EURECNET, Bratislava, 13 April 2012

Challenges of Multicenter Studies in Europe, EURECNET, Bratislava, 13 April 2012 Challenges of Multicenter Studies in Europe, EURECNET, Bratislava, 13 April 2012 Hartmut Krafft, PhD CTFG-Chair VHP-Coordinator Head, Section clinical trials Paul-Ehrlich-Institut Paul-Ehrlich-Str. 51-59

More information

Standard Operating Procedure

Standard Operating Procedure Standard Operating Procedure 6.0.1 New Study Ideas/Proposals History Version Date Author Reason 1.0 27 th August 2013 Linda Devilee To document the process and support provided by PaCCSC for new study

More information

Medical Research: Participation Issues

Medical Research: Participation Issues Medical Research: Participation Issues Key Points Types of medical solutions vary Various factors influence support & adoption Clinical trials are a critical, expensive piece of the approval process Threat

More information